Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus DERMA SMOOTHE FS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus DERMA SMOOTHE FS.
COR-OTICIN vs DERMA-SMOOTHE/FS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
1-2 drops in each affected ear twice daily for 7 days.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid